Late onset oral treatment with tranilast following large myocardial infarction has no beneficial effects on cardiac remodeling and mortality in rats

Betge,Stefan; Kunz,Christian; Figulla,Hans; Jung,Christian

doi:10.3892/etm.2014.2003

Late onset oral treatment with tranilast following large myocardial infarction has no beneficial effects on cardiac remodeling and mortality in rats

Authors:
- Stefan Betge
- Christian Kunz
- Hans Figulla
- Christian Jung
View Affiliations

Affiliations: Department of Internal Medicine I, Division of Cardiology, Friedrich Schiller University, Jena, Thuringia 07740, Germany, Department of General, Abdominal and Thoracic Surgery, City Hospital Dessau, Dessau-RoBlau, Saxony-Anhalt 06847, Germany
Published online on: October 6, 2014 https://doi.org/10.3892/etm.2014.2003
Pages: 1789-1796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tranilast (Tra) reduces intracardiac interstitial fibrosis in the animal models of hypertensive heart failure and diabetic cardiomyopathy by inhibiting cardiac fibroblasts. The present study examined whether Tra has long‑term effects on the cardiac remodeling in the remote area of the left ventricle (LV) following myocardial infarction (MI) in the rat. Treatment with Tra (n=40; 150 mg/kg twice daily) or placebo (Plac, n=36) was started at day 28 after induction of a large MI or sham‑operation (ShO, n=18) in female Lewis rats. Collagen content was determined using high‑performance liquid chromatography. Large MI led to a significant hypertrophy of the two ventricles, a severe dilatation of the LV and a shift of the chamber stiffness variables in the pressure volume curves. The six‑month survival rates were Tra, 62.5%; Plac, 75%; and ShO, 100%. No significant difference was identified between Tra and Plac regarding survival rate and collagen content. Treatment with the anti‑inflammatory and antifibrotic drug, Tra, started four weeks after the induction of a large MI in the rat, did not attenuate or positively influence remodeling in chronic ischemic heart failure and survival. Further studies are required to explore the effects of Tra on cardiac myocytes post‑MI in more detail.

View Figures

View References

1	Azuma H, Banno K and Yoshimura T: Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol. 58:483–488. 1976.
2	Taniguchi S, Yorifuji T and Hamada T: Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol. 19:391–393. 1994. View Article : Google Scholar : PubMed/NCBI
3	Yamada H, Ide A, Sugiura M and Tajima S: Treatment of cutaneous sarcoidosis with tranilast. J Dermatol. 22:149–152. 1995.PubMed/NCBI
4	Yamada H, Tajima S, Nishikawa T, Murad S and Pinnell SR: Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem. 116:892–897. 1994.PubMed/NCBI
5	Suzawa H, Kikuchi S, Ichikawa K and Koda A: Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 60:85–90. 1992. View Article : Google Scholar : PubMed/NCBI
6	Adachi S, Maruyama T, Kondo T, Todoroki T and Fukao K: The prevention of postoperative intraperitoneal adhesions by tranilast: N-(3′,4′-dimethoxycinnamoyl)anthranilic acid. Surg Today. 29:51–54. 1999.PubMed/NCBI
7	Nakamura K, Irie H, Inoue M, Mitani H, Sunami H and Sano S: Factors affecting hypertrophic scar development in median sternotomy incisions for congenital cardiac surgery. J Am Coll Surg. 185:218–223. 1997. View Article : Google Scholar : PubMed/NCBI
8	Watanabe S, Matsuda A, Suzuki Y, et al: Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors. Br J Pharmacol. 130:307–314. 2000. View Article : Google Scholar : PubMed/NCBI
9	Takahashi A, Taniguchi T, Ishikawa Y and Yokoyama M: Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ Res. 84:543–550. 1999. View Article : Google Scholar : PubMed/NCBI
10	Tamai H1, Katoh O, Suzuki S, et al: Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J. 138:968–75. 1999. View Article : Google Scholar : PubMed/NCBI
11	Tamai H, Katoh K, Yamaguchi T, et al: The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J. 143:506–513. 2002. View Article : Google Scholar : PubMed/NCBI
12	Holmes DR Jr, Savage M, LaBlanche JM, et al: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 106:1243–1250. 2002. View Article : Google Scholar : PubMed/NCBI
13	Umemura K, Kikuchi S, Suzuki Y and Nakashima M: Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart. Jpn J Pharmacol. 78:161–167. 1998. View Article : Google Scholar : PubMed/NCBI
14	Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M and Inoue H: Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens. 22:1007–1015. 2004. View Article : Google Scholar : PubMed/NCBI
15	Bujak M and Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 74:184–195. 2007. View Article : Google Scholar : PubMed/NCBI
16	Dewald O, Ren G, Duerr GD, et al: Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 164:665–677. 2004. View Article : Google Scholar : PubMed/NCBI
17	Cohn JN, Ferrari R and Sharpe N: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI
18	Ikeuchi M, Tsutsui H, Shiomi T, et al: Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 64:526–535. 2004. View Article : Google Scholar : PubMed/NCBI
19	See F, Watanabe M, Kompa AR, et al: Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction. Heart Lung Circ. Sept.14–2012.(Epub ahead of print).
20	Jung C, Gonon AT, Sjöquist PO, Lundberg JO and Pernow J: Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 85:147–154. 2010. View Article : Google Scholar : PubMed/NCBI
21	Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA and Braunwald E: Myocardial infarct size and ventricular function in rats. Circ Res. 44:503–512. 1979. View Article : Google Scholar : PubMed/NCBI
22	Fletcher PJ, Pfeffer JM, Pfeffer MA and Braunwald E: Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res. 49:618–626. 1981.PubMed/NCBI
23	Carluccio E, Biagioli P, Alunni G, et al: Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol. 47:969–977. 2006.
24	Bax JJ, Schinkel AF, Boersma E, et al: Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis. Circulation. 110:II18–II22. 2004.PubMed/NCBI
25	Senior R, Lahiri A and Kaul S: Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol. 88:624–629. 2001. View Article : Google Scholar : PubMed/NCBI
26	Brown EJ Jr, Kloner RA, Schoen FJ, Hammerman H, Hale S and Braunwald E: Scar thinning due to ibuprofen administration after experimental myocardial infarction. Am J Cardiol. 51:877–883. 1983. View Article : Google Scholar : PubMed/NCBI
27	Bulkley BH and Roberts WC: Steroid therapy during acute myocardial infarction. A cause of delayed healing and of ventricular aneurysm. Am J Med. 56:244–250. 1974. View Article : Google Scholar
28	Weber KT, Sun Y and Cleutjens JP: Structural remodeling of the infarcted rat heart. EXS. 76:489–499. 1996.PubMed/NCBI
29	Betge S, Lutz K, Roskos M and Figulla HR: Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats. Eur J Pharmacol. 558:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
30	Karatas A, Hegner B, de Windt LJ, et al: Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension. 51:1177–1183. 2008. View Article : Google Scholar : PubMed/NCBI
31	Tyagi P, Tyagi V, Yoshimura N, et al: Gender-based reciprocal expression of transforming growth factor-beta1 and the inducible nitric oxide synthase in a rat model of cyclophosphamide-induced cystitis. J Inflamm (Lond). 6:232009. View Article : Google Scholar